Abstract: Antibodies and antigen-binding fragments thereof that bind the human voltage-gated sodium channel Nav1.7? protein subunit (Nav1.7 binders) are described. In particular embodiments, the Nav1.7 binders comprise a heavy-chain immunoglobulin single variable domain (ISVD or VHH).

Abstract: A liquid-crystal (LC) material having negative dielectric anisotropy and the use thereof for optical, electro-optical and electronic purposes, such as for example in LC displays, in particular energy saving displays based on the ECB, IPS or FFS effect, where the liquid crystal medium contains one or more compounds of formula I and one or more compounds compounds of formulae IIA, IIB, IIC and IID

Abstract: Arginase 1 binders that inhibit the activity of human Arginase 1 (hArg1) and comprise human antibodies and antigen-binding fragments thereof comprising human VH and VL are described. These Arginase 1 binders present an alternative mechanism for inhibiting hArg1 activity and highlight the ability to utilize binders as probes in the discovery and development of peptide and small molecule inhibitors for enzymes in general.

Abstract: Apparatus and method for collecting a dried pharmaceutical product from a product reservoir of a pharmaceutical drying device, such as a thin film evaporator, while the product reservoir remains under continuous vacuum pressure.

Abstract: The present invention is directed to 3-heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Abstract: A compact containment system comprises a mixing apparatus, a drying apparatus and a discharge apparatus. The mixing apparatus, which may be used to produce a slurry or solution mixture of solvent and dry powder during drug processing, comprises a dual compartment isolator for safely removing the dry powder from a dry powder container, a mixing vessel, and a negative cascading pressure controller. The drying apparatus comprises a drying unit, such as a thin film evaporator.

Abstract: The new LC media exhibit a ferroelectric nematic phase at ambient temperature. They comprise at least one or more compounds selected from each of formula IA, of formula IB and of the group of formulae IC-1/IC-2/IC-3, in which the variable groups have the meanings indicated in the text and in the claims. The mixtures are useful for electro-optics, electronics, electro-mechanic and other applications for materials with very high dielectric permittivity and other energy-saving applications.

Abstract: A method is provided for processing a predetermined computing task by a distributed, vehicle-based computing system. By a server device, the computing task is divided into several data packets with respective computing data for a respective part of the computing task. The method includes that at least one motor vehicle is determined, which currently is in a predetermined ready state, and, in case it is in the predetermined ready state, the server device transmits to the motor vehicle at least one of the data packets and the motor vehicle processes the respective computing data of the at least one transmitted data packet. The vehicle generates a respective computing result related to the data packet and transmits this computing result to the server device.

Abstract: ?-Amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases, and cancer.

Abstract: To provide a substrate pattern filling composition capable of suppressing pattern collapse and a method for using the same. A substrate pattern filling composition comprising a first solute (A), a second a solute (B) and a solvent (C), and a method for using the same.

Abstract: [Object] To provide a positive type photosensitive composition capable of forming a cured film having high transparency [Means] The present invention provides a positive type photosensitive siloxane composition comprising: a polysiloxane, a diazonaphthoquinone derivative, an additive having a >N—C(?O)— or >N—C(?S)— structure and the capability of interacting with the polysiloxane, and a solvent. The polysiloxane and the additive interact with each other before exposure, but they lose the interaction after exposure.

Abstract: The present invention relates to new coating compositions for the preparation of functional surface coatings on various base material substrates. The coating compositions are based on a silazane-containing polymer and a non-polymeric phenolic compound comprising at least two and not more than four aromatic units in its molecular structure. The coating compositions provide improved physical and chemical surface properties and may be applied by user-friendly coating methods.

Abstract: Compounds of the formula I: or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.

Abstract: A thin-layer chromatography development chamber (1) that can be used for developing thin-layer chromatography plates (21) by introducing a liquid solvent onto a sample arranged on the surface of a thin-layer chromatography plate (21), whereby the solvent and the thin-layer chromatography plate (21) can be inserted into the development chamber (1), comprises a housing (2) with an opening (3). The opening (3) of the development chamber (1) can be closed with a cover (4) that comprises a data input unit (10) for entering or collecting data related to a development process performed within the development chamber (1). The cover (4) further comprises a data communication unit (16) that enables a wireless data transmission of the data related to the development process to a thin-layer chromatography data storage device (24).

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Abstract: Compounds of formula (1) that have functional substituents in a specific spatial arrangement, and electronic devices that include a compound of formula (1), and to the preparation of compounds of formula (1).

Abstract: Embodiments of the present invention provide a computer-implemented system and method for generating and searching a database containing all of the potential substructures (e.g., metabolites) of a chosen complex molecule based on minimum cleavable units (MCUs) of the chosen complex molecule, wherein each record in the generated database suitably defines the molecular weight and physical arrangement of each substructure. Embodiments of the invention also provide a user interface and a search engine for searching the database based on a query molecular weight (or query molecular weight range) to identify all of the substructures having a total molecular weight matching the query molecular weight or range. Embodiments of the invention are also capable of transmitting to a display device operated by an end user a description and/or a graphical representation of every identified substructure of the chosen complex molecule.

Abstract: A manually actuated drug-injecting device is configured such that the grip strength of the entire hand (i.e., majority of fingers closing toward the palm or heel of the hand) is employed to discharge medication through a hypodermic needle and into a patient's body. The device is well suited for delivering medications with high viscosity and/or by patients (e.g., elderly patients) with reduced finger strength and dexterity. The device includes a grip member, a push member (which causes the medication to be injected), and a force-transfer mechanism that couples the grip member to the push member. Suitably, the device is configured to be held transverse to the palm of the medication-administering hand, with a discharge port located by the outer, blade edge of the administering hand, when the device is being gripped to administer medication.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.

Abstract: A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.